May 1, 2017
Mississauga, ON – May 1, 2017 – Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc., announced today that Health Canada has recently approved CerdelgaTM (eliglustat capsules), the only first-line oral therapy indicated for the treatment of adult patients with Gaucher Disease Type 1.1 A rare genetic metabolic condition that causes fats to build up in certain parts of the body, Gaucher Disease Type 1 is progressive and may become life-threatening if symptoms are left untreated.2,3 Patients who are specific enzyme metabolisers, as detected by a simple test, will be eligible for Cerdelga treatment.1
Last Updated: 12/3/2015

Genzyme Canada
Canadian Office 
2700 Matheson Blvd. East 
West Tower, Suite 800 
Mississauga, Ontario L4W 4V9 
Tel: +1 905 625 0011 
Fax: +1 905 625 7811 
Toll Free: +1 877 220 8918 

Genzyme Medical Information 
Tel: +1 800 589 6215

If this is an emergency, please contact your local emergency department.

Ethics inquiries 
Tel: +1 800 648 1297

This Is Genzyme
Discover more about Genzyme's purpose, legacy, and innovation in our corporate brochure.

Explore opportunities at a company that's as committed to our employees as we are to our patients.